Metronomic chemotherapy following the maximum tolerated dose is an effective anti-tumour therapy affecting angiogenesis, tumour dissemination and cancer stem cells

International Journal of Cancer

Volumn 133, Issue 10, 2013, Pages 2464-2472

  Vives, Marta ^a   Ginestà, Mireia M ^a   Gracova, Kristina ^a   Graupera, Mariona ^b   Casanovas, Oriol ^a   Capellà, Gabriel ^a   Serrano, Teresa ^c   Laquente, Berta ^a   Viñals, Francesc ^a,d  

^a HOSPITAL DURAN I REYNALS   (Spain)

^b BELLVITGE BIOMEDICAL RESEARCH INSTITUTE IDIBELL   (Spain)

^c HOSPITAL UNIVERSITARI DE BELLVITGE   (Spain)

^d UNIVERSITY OF BARCELONA   (Spain)

Author keywords

anti angiogenic; cancer stem cells; chemo switch schedule; gemcitabine; metronomic chemotherapy

Indexed keywords

CD133 ANTIGEN; CYCLOPHOSPHAMIDE; GEMCITABINE; MONOCLONAL ANTIBODY DC101; THROMBOSPONDIN 1;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER CELL; CANCER CHEMOTHERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER INHIBITION; CANCER MODEL; CANCER STEM CELL; CD133+ CANCER CELL; CD133+ CD44+ CD24+ CANCER STEM CELL; CELL COUNT; CHEMOSWITCH SCHEDULE; CONTROLLED STUDY; DRUG EFFECT; DRUG MECHANISM; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; LOW DRUG DOSE; MALE; MAXIMUM TOLERATED DOSE; METASTASIS; METRONOMIC CHEMOTHERAPY; MOUSE; MULTIPLE CYCLE TREATMENT; NONHUMAN; OVARY CANCER; PANCREAS ADENOCARCINOMA; PERITONEUM METASTASIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; TUMOR VASCULARIZATION;

ANTI-ANGIOGENIC; CANCER STEM CELLS; CHEMO-SWITCH SCHEDULE; GEMCITABINE; METRONOMIC CHEMOTHERAPY;

ADENOCARCINOMA; ADMINISTRATION, METRONOMIC; ANIMALS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CYCLOPHOSPHAMIDE; DEOXYCYTIDINE; FEMALE; HUMANS; MALE; MAXIMUM TOLERATED DOSE; MICE; MICE, NUDE; NEOPLASMS; NEOPLASTIC STEM CELLS; NEOVASCULARIZATION, PATHOLOGIC; OVARIAN NEOPLASMS; PANCREATIC NEOPLASMS; RANDOM ALLOCATION; THROMBOSPONDIN 1; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84883804389     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.28259     Document Type: Article

References (27)

1. Andre N, Padovani L, Pasquier E,. Metronomic scheduling of anticancer treatment: the next generation of multitarget therapy? Future Oncol 2011; 7: 385-94.
2. Weitman SD, Glatstein E, Kamen BA,. Back to the basics: the importance of concentration × time in oncology. J Clin Oncol 1993; 11: 820-1.
3. Browder T, Butterfield CE, Kraling BM, et al. Antiangiogenic scheduling of chemotherapy improves efficacy against experimental drug-resistant cancer. Cancer Res 2000; 60: 1878-86.
4. Klement G, Baruchel S, Rak J, et al. Continuous low-dose therapy with vinblastine and VEGF receptor-2 antibody induces sustained tumor regression without overt toxicity. J Clin Invest 2000; 105: R15-R24.
5. Kerbel RS, Kamen BA,. The anti-angiogenic basis of metronomic chemotherapy. Nat Rev Cancer 2004; 4: 423-36.
6. Shaked Y, Emmenegger U, Francia G, et al. Low-dose metronomic combined with intermittent bolus-dose cyclophosphamide is an effective long-term chemotherapy treatment strategy. Cancer Res 2005; 65: 7045-51.
7. Pietras K, Hanahan D,. A multitargeted, metronomic, and maximum-tolerated dose "chemo-switch" regimen is antiangiogenic, producing objective responses and survival benefit in a mouse model of cancer. J Clin Oncol 2005; 23: 939-52.
8. Casanovas O, Hicklin DJ, Bergers G, et al. Drug resistance by evasion of antiangiogenic targeting of VEGF signaling in late-stage pancreatic islet tumors. Cancer Cell 2005; 8: 299-309.
9. Reyes G, Villanueva A, Garcia C, et al. Orthotopic xenografts of human pancreatic carcinomas acquire genetic aberrations during dissemination in nude mice. Cancer Res 1996; 56: 5713-19.
10. Braakhuis BJ, Ruiz van Haperen VW, Welters MJ, et al. Schedule-dependent therapeutic efficacy of the combination of gemcitabine and cisplatin in head and neck cancer xenografts. Eur J Cancer A 1995; 31: 2335-40.
11. Laquente B, Lacasa C, Ginesta MM, et al. Antiangiogenic effect of gemcitabine following metronomic administration in a pancreas cancer model. Mol Cancer Ther 2008; 7: 638-47.
12. Emmenegger U, Francia G, Chow A, et al. Tumors that acquire resistance to low-dose metronomic cyclophosphamide retain sensitivity to maximum tolerated dose cyclophosphamide. Neoplasia 2011; 13: 40-8.
13. Penel N, Adenis A, Bocci G,. Cyclophosphamide-based metronomic chemotherapy: after 10 years of experience, where do we stand and where are we going? Crit Rev Oncol Hematol 2012; 82: 40-50.
14. Lonardo E, Hermann PC, Heeschen C,. Pancreatic cancer stem cells-update and future perspectives. Mol Oncol 2010; 4: 431-42.
15. Lee CJ, Dosch J, Simeone DM,. Pancreatic cancer stem cells. J Clin Oncol 2008; 26: 2806-12.
16. Jain RK,. Normalizing tumor vasculature with anti-angiogenic therapy: a new paradigm for combination therapy. Nat Med 2001; 7: 987-9.
17. Van der Veldt AA, Lubberink M, Bahce I, et al. Rapid decrease in delivery of chemotherapy to tumors after anti-VEGF therapy: implications for scheduling of anti-angiogenic drugs. Cancer Cell 2012; 21: 82-91.
18. Tran Cao HS, Bouvet M, Kaushal S, et al. Metronomic gemcitabine in combination with sunitinib inhibits multisite metastasis and increases survival in an orthotopic model of pancreatic cancer. Mol Cancer Ther 2010; 9: 2068-78.
19. Hermann PC, Huber SL, Herrler T, et al. Distinct populations of cancer stem cells determine tumor growth and metastatic activity in human pancreatic cancer. Cell Stem Cell 2007; 1: 313-23.
20. Mueller MT, Hermann PC, Witthauer J, et al. Combined targeted treatment to eliminate tumorigenic cancer stem cells in human pancreatic cancer. Gastroenterology 2009; 137: 1102-13.
21. Folkins C, Man S, Xu P, et al. Anticancer therapies combining antiangiogenic and tumor cell cytotoxic effects reduce the tumor stem-like cell fraction in glioma xenograft tumors. Cancer Res 2007; 67: 3560-4.
22. Martin-Padura I, Marighetti P, Agliano A, et al. Residual dormant cancer stem-cell foci are responsible for tumor relapse after antiangiogenic metronomic therapy in hepatocellular carcinoma xenografts. Lab Invest 2012; 92: 952-66.
23. Laquente B, Viñals F, Germa JR,. Metronomic chemotherapy: an antiangiogenic scheduling. Clin Transl Oncol 2007; 9: 93-8.
24. Pasquier E, Kavallaris M, Andre N,. Metronomic chemotherapy: new rationale for new directions. Nat Rev Clin Oncol 2010; 7: 455-65.
25. Bellmunt J, Trigo JM, Calvo E, et al. Activity of a multitargeted chemo-switch regimen (sorafenib, gemcitabine, and metronomic capecitabine) in metastatic renal-cell carcinoma: a phase 2 study (SOGUG-02-06). Lancet Oncol 2010; 11: 350-7.
26. Allegrini G, Di Desidero T, Barletta MT, et al. Clinical, pharmacokinetic and pharmacodynamic evaluations of metronomic UFT and cyclophosphamide plus celecoxib in patients with advanced refractory gastrointestinal cancers. Angiogenesis 2012; 15: 275-86.
27. Koolen SL, Witteveen PO, Jansen RS, et al. Phase I study of oral gemcitabine prodrug (LY2334737) alone and in combination with erlotinib in patients with advanced solid tumors. Clin Cancer Res 2011; 17: 6071-82.